Previous studies similarly reported the role of upregulated ezrin expression in the mechanisms underlying the resistance to chemotherapy in different cancer types including breast cancer [22,23,24], tongue squamous cell carcinoma [25] and osteosarcoma [26], and demonstrated that ezrin suppression by genetic or pharmacological manipulation could increase chemotherapeutic sensitivity. This evidence concerns the gene EZR and breast cancer.